Simantini Eddy
Impact in
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
-
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
-
- Prostate Cancer Treatment and Research 2
- Renal cell carcinoma treatment 1
- Oncology 2
- Cancer Immunotherapy and Biomarkers 2
- CAR-T cell therapy research 1
- Co-authors
- Mark N. Stein (5 shared papers)Susan Goodin (2 shared papers)Robert S. DiPaola (3 shared papers)Murugesan Gounder (1 shared paper)Kevin Bray (1 shared paper)Hongxia Lin (1 shared paper)Dmitri Dvorzhinski (1 shared paper)Eileen White (1 shared paper)
- Journals
- Journal of Clinical Oncology (2 papers)The Prostate (1 paper)Cancer (1 paper)Clinical Pharmacology Advances and Applications (1 paper)BMC Cancer (1 paper)
- Partner nations
- United StatesSwitzerlandCanada
In The Last Decade
Simantini Eddy
8 papers receiving 407 citations
Peers
Comparison fields: 5 of 56
- Cancer Research 144
- Oncology 148
- Immunology 68
- Pulmonary and Respiratory Medicine 89
- Molecular Biology 174
Countries citing papers authored by Simantini Eddy
This map shows the geographic impact of Simantini Eddy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simantini Eddy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simantini Eddy more than expected).
Fields of papers citing papers by Simantini Eddy
This network shows the impact of papers produced by Simantini Eddy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simantini Eddy. The network helps show where Simantini Eddy may publish in the future.
Co-authors
The 25 scholars most cited alongside Simantini Eddy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 241 | |
| 2 | 2010 | 119 | |
| 3 | A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer. | 2012 | 18 |
| 4 | 2012 | 14 | |
| 5 | 2015 | 9 | |
| 6 | 2009 | 6 | |
| 7 | 2011 | 3 | |
| 8 | 2024 | 2 |
About Simantini Eddy
Simantini Eddy is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Infectious Diseases, having authored 8 papers that have together received 412 indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Cancer Genomics and Diagnostics (1 paper), Renal cell carcinoma treatment (1 paper), Cancer, Lipids, and Metabolism (1 paper), Radiopharmaceutical Chemistry and Applications (1 paper) and CAR-T cell therapy research (1 paper). The work is most often cited by research in Cancer Research (144 citations), Oncology (148 citations), Immunology (68 citations), Pulmonary and Respiratory Medicine (89 citations) and Molecular Biology (174 citations). Simantini Eddy has collaborated with scholars based in United States, Switzerland and Canada. Frequent co-authors include Mark N. Stein, Susan Goodin, Robert S. DiPaola, Murugesan Gounder, Kevin Bray, Hongxia Lin, Dmitri Dvorzhinski, Eileen White, Chandrika Jeyamohan and Brian I. Rini. Their work appears in journals such as Journal of Clinical Oncology, The Prostate, Cancer, Clinical Pharmacology Advances and Applications and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.